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Task Force used several criteria to evaluate screening and other preven tive clinical services: the burden o f disease; the efficacy of the screening test; the effectiveness o f early detection; and recommendations made by others (e.g., the Canadian Task Force, the American Cancer Society, the National Cancer Institute, and professional groups).
W e propose that the trade-off between the frequency of screening individuals and the population coverage (the percentage of the popula tion that is screened), and the impact o f this trade-off on the population rates of cancer, should also be carefully considered by those making policy recommendations.
Prevention strategies (e.g., some immunizations) for some diseases do not require repeated "intervention." Programs like immunization have focused solely on achieving sufficient or complete population coverage (frequency is not an issue). The discussion o f cancer screening, on the other hand, has tended to focus on increasing the frequency of screening individual patients, ignoring the issues of population coverage. Unfor tunately, often those at highest risk for cancer remain unscreened. Screen ing individuals less frequently, but covering more of the population, however, may (for some cancers) be more likely to reduce total popula tion cancer mortality, which is one o f the year 2 0 0 0 goals. W e examine the criteria currently used to evaluate the effectiveness of screening for cancer and highlight issues on which the policy decision making process requires additional data. We focus on cancers of the cervix, breast, and colon, as there is sufficient information about them to perm it us to discuss seriously the trade-off between screening fre quency and population coverage. W e extend the approach of the U.S. Preventive Services Task Force by also considering the trade-off between (a) expending resources to achieve more complete coverage with a pro gram and (b) more frequent screening that, in all likelihood, entails reduced coverage. Thus we ask, "W orking within a constrained health care budget, how do we achieve the greatest reduction in cancer mor tality?" The text o f the Preventive Services Task Force (1996) indicates that extending coverage to people who have not been screened for cer vical cancer is important: "The effectiveness o f cervical cancer screening is more likely to be improved by extending testing to women who are not currently being screened and by improving the accuracy of the Pap smears than by efforts to increase the frequency o f screening."
This contrasts with their fin a l recommendation on screening for cervical cancer:
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Regular Papanicolaou (Pap) testing is recommended for all women who are or have been sexually active and have a cervix. Testing should begin at the age when the woman first engages in sexual intercourse. There is little evidence that annual screening achieves better out comes than screening every 3 years. Pap tests should be performed at least every 3 years. The interval for each patient should be recom mended by the physician based on risk factors. (U .S. Preventive Ser vices Task Force 1996) Thus, the Preventive Services Task Force offers no population-level guidance on the trade-off between frequency o f screening and coverage, although they do identify it as an important consideration. From the national public health perspective, quantifying this trade-off is funda mental to the efficient allocation of resources to achieve national goals of reduced cancer burden and mortality. In fact, emphasis on the frequency of screening and on other technical aspects should not detract from the importance of the coverage rate of a program. In principle, improving coverage can increase the benefit more than shortening the screening interval (Tomatis 1990 , 2 6 7 -8 ).
Background
Screening for cancer is one approach to prevention, and it is often called "secondary prevention" because its aim is early detection and improved treatment outcomes rather than primary prevention o f disease. In con trast with primary prevention, where one intervention (such as cessation from smoking [Kawachi et al. 1993] or avoidance o f obesity [Manson et al. 1995] ) may reduce the incidence o f m ultiple cancers, heart disease, and diabetes, secondary prevention strategies are specific to the indi vidual cancers. Thus, secondary prevention offers a fragmented, but still valuable, approach to reducing the societal burden o f cancer, when can cers detected at an early stage respond to treatment, hence ensuring that the apparent gain in survival exceeds what would be obtained solely through earlier diagnosis and detection o f less aggressive tumors (Cole and Morrison 1980; Black and W elch 1993) . Furthermore, some cancers (i.e., breast cancer) currently have no established primary prevention strategies, so we must rely solely upon screening for early detection. Table 1 summarizes some o f the measures that influence the effec tiveness of screening programs for cancer. Information on these mea-
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sures is needed to estimate the potential impact o f a screening program on cancer incidence and mortality rates.
Cervical Cancer
Cervical cancer accounts for about 7 ,0 0 0 deaths per year among women in the United States. The incidence is higher among African-American women than among white women. The incidence (based on the Sur veillance, Epidemiology and End Results [SEER ] tumor registries) for African-American women doubles from age 35 to age 65 (from 20 to 43 cases per 100,000 women). In contrast, the rates among white women are relatively stable over the same age range, perhaps reflecting in part the impact of screening programs. Cervical cancer appears to be the disease in which secondary prevention through screening has been most extensively studied. Numerous studies have evaluated the efficacy of Pap-smear and screening programs (Hakama, Miller, and Day 1986 ; International Agency for Research on Cancer 1986). In addition, time trends in cervical cancer incidence and mortality-particularly in Nor dic countries, where implementation o f programs has varied-show a strong correlation between the extent o f the organized screening pro gram and changes in cervical cancer rates (Hakama and Louhivouri
8 8 ).
The Pap smear, now the standard screening test for cervical cancer, detects exfoliative cytology, a defined precursor o f squamous cell carci noma of the cervix. A meta-analysis suggests that a typical sensitivity (i.e., the probability that a diseased patient tests positive) is approxi mately 35 percent when specificity (i.e., the probability that a nondiseased person tests negative) is greater than 90 percent (Fahey, Irwig, and Macaskill 1995) . A screening program, o f course, requires more than a screening test; it must include referral and effective treatment for the precursor lesion identified by the test. The treatment typically involves cryosurgery to remove the premalignant lesion from the cervix and so to prevent progression to malignant disease.
For cervical cancer, the protective effect (i.e., the reduced probability of a diagnosis after a negative screening test) is high for three years after the last negative screen (Pap test), and then it declines by 4 percent per year. Thus, even six to nine years after a negative screen, substantial protection remains for screened, compared with unscreened, women. N Because the protective effect is reported by time since last negative screen, one can estimate the cumulative rate of disease that would be expected from different schedules of screening (that is, assuming differ ent intervals between screens).
The International Agency for Research on Cancer (IA RC ) has coor dinated a large number o f studies on cervical cancer screening and has reported its work extensively. IA RC estimates the percentage reduction in cumulative incidence o f cervical cancer from age 35 to age 65 for a series o f screening intervals (table 2). W ith data like these, it is possible to estimate the marginal gain, from the population perspective, when screening is intensified from every three years, say, to every two years. As seen in table 2, this increase produces a reduction in incidence of cer vical cancer of 1.7 percent and an increase in the number of Pap smears from 10 to 15 per woman over the 30-year interval from age 35 to age 65. The marginal benefit (1.7 percent reduction in incidence) is low relative to the marginal cost (five additional Pap smears) per woman.
In the United States in 1992, 65 percent o f women had had a Pap smear within the past three years. Furthermore, some 4 9 percent of women had had a Pap smear within the past year (Anderson and May 1995 3 ). These estimates assume full follow-up and treatment of lesions among all participants in the screening program.
From table 3 we see that moving the 4 9 percent of women who now undergo annual screening to a schedule o f screening every three years would reduce drastically the number o f tests per woman; from age 20 to age 65 these women would require 30 fewer tests each. The protection against cervical cancer among these women would decrease only slightly, from 93.5 to 90.8 percent. By allocating the saved resources to ensure that the 35 percent of the population that is currently screened approxi mately every 10 years shifts to a three-year interval between screens, we increase their number of tests from 5 to 15. These women would observe a substantial gain in protection against cervical cancer (from a 6 4 per cent reduction to a 9 0 .8 percent reduction in cancer incidence). A t the population level, this translates into both fewer cases o f cervical cancer (an 8 percent reduction) and roughly half the current number of Pap smears (from 26 to 15 tests per woman). Accounting for the false posi tive results of screening tests that require additional workup, the cost savings with this lower number o f screening tests would be substan tially more than just the cost o f tests that were not performed.
This example demonstrates that a program aimed at increasing the coverage of women screened for cervical cancer, which would result in the 35 percent of women not being screened regularly now obtaining Pap smears every three years while the frequency o f screening is reduced in other groups, may be a desirable strategy. It results in fewer tests to A cost-effectiveness analysis conducted in Holland addressed the op timal number of screens for a woman in that country and concluded that seven to ten Pap smears over a lifetim e produced the maximum costeffectiveness. Ju st seven screens in a lifetim e could produce the same benefit as standard Dutch clinical practice (spontaneous screening by physicians similar to current U.S. practices), but at half the cost. In large part this is due to excessive screening applied to younger women and insufficient screening of older women (Koopmanschap et al. 1990 ).
It is noteworthy that Finland, with a national program o f Pap screens every five years, has achieved a 6 0 to 70 percent reduction in incidence of cervical cancer. In contrast, Knox and Woodman modeled screening behavior in the United Kingdom and observed that the distribution of Pap smears was far from optimal. They estimated that only 8 percent of cervical cancer deaths were avoided by Pap smears through 1975. W hen optimizing the age distribution of Pap smears and removing social stratification of use, they estimate that seven screens per woman over her life would prevent 52.4 percent of deaths from cervical cancer (Knox and Woodman 1988) .
Conclusion. Screening programs for cervical cancer are so effective that annual and biennial screens are unnecessary for average-risk women, in part because the test screens for precancerous cells and the progres sion from the detectable, precancerous state to cancer is slow. Reallo cating resources away from annual Pap smears should be an explicit public health policy, as should the emphasis on expanding coverage in 
Breast Cancer
Breast cancer is the second leading cause o f death among U.S. women, but the leading cause o f cancer incidence. Among women over age 50, incidence is higher in white women than in African-American women, The issue of screening frequency is complicated by physiological fac tors. Screening is less sensitive among premenopausal women (i.e., those under 50), whose breasts are denser. In one clinical trial, sensitivity was 60 percent in younger women, compared with 86 percent in older women (Tabar et al. 1992) . The rate o f growth o f tumors may also be faster among premenopausal women, partly because o f their higher lev els of circulating hormones. Consistent with these physiological condi tions, studies of mammography among women under age 50 indicate that the sojourn time (i.e., the interval from the least detectable abnor mality on screening to clinical diagnosis) is perhaps only one year for women aged 4 0 to 50, in contrast with two years among those over 50 years of age (Day and Chamberlain 1988) . Modeling U .S. incidence over the past decade also indicates that lead times o f two years for women aged 4 0 to 4 9 and 50 to 59, four years for ages 6 0 to 69, and five years for ages greater than 7 0 provide a good fit to the data (Feuer and W un 1992) . The combination of lower test sensitivity and faster-growing tumors, together with lower incidence rates at younger ages, leads to inconclusive findings from the published trials regarding the benefit of screening younger women (aged 4 0 to 49 ) (Elwood, Cox, and Richard son 1993) .
The actual magnitude o f a program required to obtain a reduction in breast cancer mortality is exemplified by data from the Swedish trial of mammography (screening every two years). For women aged 50 to 69 at entry to the trial, one breast cancer death was prevented per 4,000
woman-years, per 1,460 mammographic examinations, per 13.5 biop sies, and per 7 .4 breast cancers detected (Tabar et al. 1989 ). These results, based on nine years o f follow-up, reflect 58 fewer deaths among the 4 7 ,0 0 0 women in the screened group. At the same time, the mammography-screened group had 20 percent more cases of breast can cer diagnosed than the unscreened group.
Trade-O ffs in Screening Frequency a n d Cancer R ate Reductions
This challenging example o f the trade-off between decreasing screening frequency and expanding population coverage has been limited by the sparse data on the reduction in risk o f breast cancer according to time since the last mammogram. A report from an ongoing screening pro gram in northern California, which includes 8,547 women who have had a first mammogram interpreted as normal and who have later un dergone a second screening examination, provides insufficient informa tion to document changes in risk with the interval since the last negative screening test; only 16 cancers were diagnosed among these women during follow-up screens (Kerlikowske et al. 1993) . Data from Europe, including a national screening program in the United Kingdom, indicate that the rate o f breast cancer is reduced during the first year after a screening mammogram, rises during the second year, and, during the third year, is close to that among women who have never had a screening mammogram (table 5) . Cancer may be detected after a negative screen for several reasons. The cancer may arise as a result of failure to detect it by screening mammography, or it may be a new cancer. Review o f data from several trials indicates that at least half of the cancers diagnosed in the first 24 months after screening mammography are true new cancers. Thus screening every two years is C an cer In ciden ce a n d M o r ta lity
<D O c C4 (Peeters et al. 1989) and begin to define the issues around screening frequency. However, whether optimal screening frequency is constant across age remains to be shown, particularly as lead tim e varies with age.
Cost-Effectiveness o f M am m ography
Using an elaborate model of screening applied to the entire Dutch population of women aged 50 to 70, van der Maas and colleagues (1989) estimate that, with a 70 percent attendance at screening, a program of mammography every two years can produce a 12 percent reduction in breast cancer mortality. The cost-effectiveness of mammography is in fluenced mainly by the reduction in the need to treat advanced disease.
Further analysis of data for the national Dutch screening program sug gests that screening every two years will reduce mortality from breast cancer in the total population by 16 percent, whereas screening every three years reduces it by 10 percent (de Koning et al. 1991) . Adjust ment for quality o f life has little impact on these estimates. Addressing issues of screening frequency and population coverage, de Koning esti mates that expanding coverage to include women aged 70 to 75 results in a marginal cost-effectiveness o f U.S. $ 8 ,0 0 0 per additional life-year gained, which is substantially more favorable than the expansion of screening to women under age 50. Using data on incidence in the United States and charges from South ern California Medicare, Katlove and colleagues have developed a basic package o f services representing benefits that should be provided to all citizens (Katlove et al. 1995) . Based on a charge of $88.50 for mam mography, they estimate that, for women aged 50 to 59, charges would be $ 8 ,2 8 0 per extra year o f life and for women aged 60 to 69, $9,890. To save one potential life at ten years o f follow-up, 6 9 0 women aged 50 to 59 would need to follow regular screening; among women aged 60 to 6 9, the number would be 553. Barriers to screening include lack of physician advice to women (Ackermann and Cheal 1994), and, among older women, a lower knowledge of the usefulness and benefits of mammography, particularly in the absence of symptoms (Costanza 1994 Newcomb et al. 1992) . Although these and other recent reports suggest that screening sigmoidoscopy may reduce mortality from colon cancer, both major studies have used relatively small numbers of subjects and have had limited ability to evaluate the potential confound ing effect of healthful lifestyle and likelihood of screening.
Conclusion. Mammography is moderately
The efficacy of this screening procedure may come in part from ex cision of precursor lesions, or polyps, that are detected (Winewar et al. 1993 ). It appears that many providers proceed to more aggressive sur veillance and testing among those who have at least one polyp. To date there is no rational recommendation either for the frequency of screen ing or for the age at which screening should begin. Despite sparse data, the American Cancer Society (ACS) recommends sigmoidoscopy every three to five years, starting at age 50 (American Cancer Society 1980). The Preventive Services Task Force concluded in 1996 that evidence was sufficient to recommend annual fecal occult blood testing or sig moidoscopy, or both (U .S. Preventive Services Task Force 1996, 8 9 -103). They note that evidence is insufficient to recommend for or against routine screening with digital rectal examination, barium enema, or colonoscopy. Currently, sigmoidoscopy appears to be spreading as a rou tine screening procedure, with large HMOs providing this procedure as a screening service. Although most screening recommendations are made for the total population, they nevertheless focus on high-risk individu als, usually defined according to age. This practice, in part, reflects the distribution o f the burden o f disease. For colorectal cancer, it may also be possible to define risk according to lifestyle factors and to clarify the current ACS recommendation, which does not mention that after sev eral negative sigmoidoscopic screens one gains little from additional screening.
The National Health Promotion and Disease Prevention Objectives specify that fecal occult blood testing every one to two years should be extended to achieve coverage o f at least 50 percent o f people aged 50 and older. This recommendation has been expanded, in the report Health, U nited States, 1 992 , to include proctosigmoidoscopy in addition to fecal occult blood testing (National Center for Health Statistics 1993, 328-9) . Estimates o f the prevalence o f this screening procedure in the United States indicate that in 1987 only 25 percent o f adults reported having ever had a proctosigmoidoscopic examination.
Trade-Offs in Screening Frequency and R ate Reductions
Because clinical practice is rapidly changing as new studies are pub lished, we review the trade-off between frequency o f sigmoidoscopic examinations and reduction in cancer rates, as estimated by Eddy (1990) .
Using Markov models to obtain estimates, he presents numerous sce narios, but for illustration we use his estimates for screening among 50-year-old women of average risk who are screened from age 50 to age 75 (table 6) .
These data suggest that little marginal gain results from increasing the frequency of sigmoidoscopy screening from every five years to every three years. But, as for the Pap smear, it is likely that less frequent screening, perhaps every ten years starting at age 50, but covering more o f the population, would be an efficient screening strategy that would result in fewer cases and fewer deaths from colon cancer.
Although not presented in detail here, it is worth noting that Eddy's analysis shows that a barium enema every five years would prevent twice as many cancers per 1 0 ,0 0 0 women (301) as a sigmoidoscopy every three years (153), and with half as many perforations (14 vs. 37). The barium enema strategy is also cheaper. However, medical practice is not pursu ing this approach to screening, but rather is exploring approaches, such as training in sigmoidoscopy for nurse practitioners, who are equally effective and have higher rates o f return for follow-up examinations than gastroenterologists (Maule 1994) .
Conclusion.
Flexible sigmoidoscopy, which may prevent nearly half of all colorectal cancer deaths, appears promising as a screening proce dure for colon cancer. Questions o f screening frequency remain impor tant, including the need for information on longer screening intervals
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(ten years) and the relative merits of sigmoidoscopy, barium enema, and colonoscopy. It is likely that less frequent screening, but covering more of the population, will result in fewer cases and deaths. These issues must be addressed to help inform policy and social strategies to im ple ment broader screening programs.
Discussion
Screening for precursor lesions is more useful than early detection o f cancers, in part because there is a longer interval from a negative screen ing test to a subsequent new cancer. Less frequent screening is preferable when the target is a precursor lesion, thus resulting in more costeffective programs to reduce cancer mortality. This approach, as exem plified by cervical and colon cancer screening, also offers the advantage of preventing cancer; treating a precursor lesion is cheaper than treating a diagnosed cancer and also less traumatic for the patient. person-years of life lost for breast cancer to 7 5 8 ,0 0 0 person-years for colon cancer, and 1 1 6 ,0 0 0 for cervical cancer (although this figure re flects the impact of current Pap screening).
An alternative to aiming at broad population coverage with a screen ing program is to target a subpopulation that is at high risk for disease.
Such high-risk groups may be better served by more intense screening frequencies. The literature addresses the problems of defining high-risk groups, although it usually considers only those with a positive family history of the cancer in question (for example, see Eddy [1990] on screening for colon cancer). But for breast and colon cancer, only 15 percent of cancers occur among those with a family history of disease.
For cervical cancer, Hakama and colleagues show that the use of risk factors to define a high-risk group small enough to reduce the costs of a screening program was not effective (Hakama, Pukkala, and Saastamoinen 1979) . They defined a high-risk group using epidemiological risk factors, but this group included only 39 percent of all cases. Similar results have been found for breast cancer. Most policies and recommendations by national organizations and gov ernment agencies routinely use age and sex as markers to define high risk. As cancer rates increase markedly with age, the relative effectiveness of screening increases also. That is, fewer women are screened at older ages per cancer detected, but we also note that the savings in life-years de crease as life expectancy diminishes with increasing age. The effect of age on the sensitivity and specificity o f the screening test may also be im portant, especially for breast cancer, where mammography has a higher sensitivity in older women. This has particular importance for those who test positive and then require additional diagnostic tests. In addition to the diagnostic test procedures, for all cancers the period of uncertainty regarding the diagnosis is clearly stressful. In general, for all cancers (ex cept lung cancer), high-risk groups defined by risk factors other than age contribute only a small fraction to the total disease burden and hence do not offer a useful approach to prevention or screening.
Emerging data do suggest that, as an alternative, low-risk groups may be defined by a number of epidemiological markers o f risk. For example, for ovarian cancer we may consider defining a low-risk group that may include women who have used oral contraceptives for five or more years (which yields a 50 percent reduction in risk) (Hankinson et al. 1992 ), who do not have a family history o f breast or ovarian cancer, and who have had a tubal ligation (which further reduces risk by ap proximately 50 percent) (Hankinson et al. 1993 ). This may be a rare example among cancers, although colon cancer may also offer the po tential to define risk groups according to lifestyle factors and to recom mend screening strategies separately for these groups (e.g., high-riskdefined by intake of red meat, moderate alcohol intake, and low folate intake; low-risk-defined by low red meat, low alcohol, and high folate intake) (Giovannucci et al. 1993) .
Public health policy emerges from interactions among forces in so ciety. For health promotion and disease prevention, we require a sound scientific knowledge base, social strategies, and political will. These factors must be in balance (Richm ond and Kotelchuck 1984) . Social strategies that facilitate broad participation in screening are essential. Barriers to compliance are a necessary consideration in determining the extent of coverage set as a goal in a screening program. These barriers go beyond the cost of the screening test and may include health beliefs, fear of unpleasant tests (e.g., sigmoidoscopy), access to services, and com peting time constraints. In addition, factors like overdiagnosis, com pli cations of the screening tests, false positive test results, the complications of treatment for the cancer in question and their impact on quality o f life may also represent barriers in some populations.
There is not enough information about sigmoidoscopy and other colon-screening modalities that have been available for a considerable time to permit us to choose among screening intervals. Hence we must rely upon statistical models, such as the Markov model used by Eddy (1990) , to inform decision making. I f we are to maximize the use of secondary prevention to reduce cancer mortality, then obtaining these data is an urgent priority. to women who are medically underserved (Henson, Wyatt, and Lee 1996) .
Although the U .S. Public Health Service Year 2000 goals recom mend greater screening to reduce cancer mortality, an optimal screening policy for the United States at this time should aim to achieve a maxi mum reduction in cancer burden for the lowest expenditure. An alter native to such an optimal approach would be to fund only screening tests shown to significantly reduce cancer mortality without regard for the dollar costs of the screening program. Under this alternative, no insurance coverage would currently be justified for PSA screening for prostate cancer, ovarian cancer screening, or mammography before age 50 because mortality reductions have not been demonstrated. If the focus is on optimal approaches, then, with sufficient funds available and evidence that screening reduced mortality, we would need to rank screening tests according to a criterion such as cost per life saved or cost per year o f life saved. We would likely begin by focusing on those breast, colon, prostate, and ovary. The very low estimate o f life-years lost from cervical cancer already takes into account an effective screen ing program. To achieve optimal efficiency of national screening pro grams, we would focus on the total costs o f the screening programs (screening, diagnosis, treatment o f detected disease, and costs for over coming population barriers to screening). In this situation, the interval or spacing between screening tests has a major impact on the relative cost-effectiveness of screening (less frequent tests are far more costeffective, assuming that diagnosis and treatment costs are similar). An alternative to this approach, which relies heavily on life-years saved, could consider the most cost-effective screening strategy for individuals of a given age. This approach deals instead with the issue of how we can best provide health care to our population o f 60-year-old women, lead ing us to consider whether screening dollars for women of this age are better spent by screening for colon cancer, breast cancer, or cervical cancer. The optimal screening strategy will be different for 40-year-old women.
Conclusion
In contrast to the usual measures o f screening test performance (sensi tivity, specificity), this review highlights the importance o f the fre quency of screening tests in considering a screening program. Data to inform recommendations for the tim ing o f screening tests are sparse and are urgently needed if we are to implement programs to achieve maxi mum efficiency in reducing cancer mortality. To achieve national goals with limited resources, screening tests that will contribute most to reducing mortality in a cost-effective manner must be given priority.
Sometimes this task can be accomplished by increasing the population coverage rather than the frequency o f screening tests. The example of cervical cancer screening highlights the important trade-offs between frequency of screening and population coverage and the relative impact of these components on population cancer rates as well as on costs. To achieve the National Cancer Institute's goals for cancer mortality reduc tion in the United States, these trade-offs must be reviewed for each
